[ad_1]
Good Monday to you, readers.
I'm coming back from New York to New York from the west coast, so I'll have to hurry. Suffice it to say that the current meeting of the American Society of Clinical Oncology (ASCO) – the world's largest cancer conference – contains many elements for your solution to drug development.
Read all the details below and come back tomorrow with more.
<p clbad = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Sy Mukherjee @the_sy_guy[email protected]"data-reactid =" 19 "> Sy Mukherjee @the_sy_guy[email protected]
-
DIGITAL HEALTH
Apple is spying on Watch OS6's health capabilities. Apple certainly does not fear its investments in health care. At an event announcing various new product updates, Operations Director Jeff Williams introduced a number of updates to the watchOS system tailored to the well-being. "WatchOS 6 reinforces our commitment to help users better manage their health and fitness with new powerful and personal tools," he said. These features include a focus on women's health (including tracking and logging of menstrual cycle data) and an app that promotes ear health by telling you to reduce noise.
-
INDICATIONS
Amgen surprises with early drug data for lung cancer and colorectal cancer Shares of biotech giant Amgen climbed 3.5% on Monday after the company released promising data, albeit at an early stage, on an experimental drug to treat lung cancer and colorectal forms at the current meeting of the American Society of Clinical Oncology (ASCO) in Chicago. What makes these data so interesting is the first example of a new clbad of cancer treatments (which has been developing for a long time), called KRAS inhibitors. As badysts have noted, this was a small group of participants participating in a preliminary test. The proof will be in the pudding that follows.
Merck is clinging to an expanded approval of antibiotics. The acquisition of an antibiotic by the US pharmaceutical manufacturer Merck is bearing fruit. The Food and Drug Administration (FDA) approved Monday treatment with Zerbaxa against nosocomial infections. This is just a victory for Merck today: the company also introduced KeyCruda's new ASCO data, its cancer-fighting immunotherapeutic, revealing a lasting benefit for the survival of lung cancer patients. (Reuters)
-
THE GREAT IMAGE
The brain hit in the long run. Repeated brain damage has been linked to devastating cognitive decline and behavioral changes. But a new study suggests that even minor injuries in the area can have long-term effects. "Two weeks after their injuries, 87% of patients with brain injury and 93% of other trauma patients reported functional limitations, a difference that was too small to exclude the possibility that it was due to chance," reports Reuters. . (Reuters)
-
COMPULSORY READING
What the Americans are wrong in the relationship between the United States and China, by Kristen Bellstrom
Why the month of pride is more important than ever: raceAhead, by Ellen McGirt
The secret source of Tesla species has finally been revealed, by Bloomberg
7 books in business and journalism to read this summer, by Rachel King
Produced by Sy Mukherjee @the_sy_guy [email protected] Find past cover. Sign up for other Fortune newsletters.
[ad_2]
Source link
